OUTCOME OF CMV PNEUMONIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF MODERN TRANSPLANTATION AND CMV PREVENTION PRACTICES (EBMT 2026) - Mar 14, 2026 - Abstract #B084; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Background: The incidence of early cytomegalovirus (CMV) pneumonia has decreased significantly with the introduction of routine PCR surveillance and next letermovir prophylaxis in allogeneic hematopoietic cell transplantation (HCT) recipients; however, late episodes of the CMV disease still occur and contribute to transplant-related mortality... CMV pneumonia incidence and mortality have continued to decline in the modern era, although late cases remain clinically relevant. The prognosis for patients requiring mechanical ventilation at the time of diagnosis remains poor, despite the improvement of transplant and supportive care techniques. The addition of IVIG or CMV-specific immunoglobulin to antiviral therapy did not show a clear survival benefit in this cohort, suggesting limited evidence to support their routine use."
Cytomegalovirus Infection • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation
|
|
Alicja Sadowska-Klasa1,2; Hu Xie1; Guang-Shing Cheng1; Danniel Zamora3,1; Paul Carpenter1; Wendy Leisenring1; Michael Boeckh1
|